NEW YORK (360Dx) – Cell-based cancer diagnostics firm Celcuity went public today with an initial public offering of 2.4 million shares, priced at $9.50 per share.

The firm has also offered its underwriter, Craig-Hallum Capital Group, a 30-day option to purchase up to an additional 360,000 shares at the $9.50 per-share price, minus an underwriting discount, to cover any overallotments.

Celcuity's share trade on the Nasdaq Capital Market under ticker symbol "CELC." The public offering is expected to close on Sept.22, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.